Merck's Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C 64.6% in Phase 3, Outperforming Competitors
MRK sits 61% above its 52-week low of $73.31.
Summary
This news reports highly positive Phase 3 trial results for Merck's investigational oral PCSK9 inhibitor, enlicitide decanoate. The drug demonstrated a significant 64.6% reduction in LDL-C at eight weeks when added to statins, notably outperforming existing treatments like bempedoic acid (56.7%), ezetimibe (36.0%), and their combination (28.1%). This advancement to Phase 3 with strong data builds on the highly positive Phase 2 results announced earlier today for the same drug. For Merck, a company facing future revenue declines from Keytruda's patent expiration, successful late-stage development of a drug with such a strong competitive profile in a large market like cholesterol management is a critical positive catalyst. This data confirms robust LDL-lowering efficacy, positioning enlicitide as a potentially significant future growth driver. Traders will now focus on the drug's regulatory pathway and potential market entry.
At the time of this announcement, MRK was trading at $118.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $292B. The 52-week trading range was $73.31 to $125.14. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.